Clostridium difficile isolates with high linezolid mics harbor the multiresistance gene cfr

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 586-589

  Marín, Mercedes ^a,b,c,d   Martín, Adoración ^a,d   Alcalá, Luis ^a,c,d   Cercenado, Emilia ^a,b,c,d   Iglesias, Cristina ^a,c,d   Reigadas, Elena ^a,d   Bouzaa, Emilio ^a,b,c,d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; CFR METHYLTRANSFERASE; CHLORAMPHENICOL; CLINDAMYCIN; ERYTHROMYCIN; LINEZOLID; METHYLTRANSFERASE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; RNA 23S; TRANSPOSON;

AMPLICON; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG MECHANISM; GENE MUTATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; PEPTOCLOSTRIDIUM DIFFICILE; RIBOTYPING; TRANSPOSON; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; SPAIN;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CHLORAMPHENICOL; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE; DNA TRANSPOSABLE ELEMENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ERYTHROMYCIN; HUMANS; LINEZOLID; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; RIBOTYPING; RNA, RIBOSOMAL, 23S; SPAIN;

EID: 84920109875     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04082-14     Document Type: Article

References (24)

1. Brickner SJ, Barbachyn MR, Hutchinson DK, Manninen PR. 2008. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections. J Med Chem 51:1981-1990. http://dx.doi.org/10.1021/jm800038g.
2. Shen J, Wang Y, Schwarz S. 2013. Presence and dissemination of the multiresistance gene cfr in Gram-positive and Gram-negative bacteria. J Antimicrob Chemother 68:1697-1706. http://dx.doi.org/10.1093/jac/dkt092.
3. Long KS, Vester B. 2012. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother 56: 603-612. http://dx.doi.org/10.1128/AAC.05702-11.
4. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. 2006. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 50:2500-2505. http://dx.doi.org/10.1128/AAC .00131-06.
5. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31:431-455. http://dx .doi.org/10.1086/651706.
6. Debast SB, Bauer MP, Kuijper EJ. 2014. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20(Suppl 2):S1-S26. http://dx.doi.org/10.1111/1469-0691.12418.
7. Valerio M, Pedromingo M, Munoz P, Alcala L, Marin M, Pelaez T, Giannella M, Bouza E. 2012. Potential protective role of linezolid against Clostridium difficile infection. Int J Antimicrob Agents 39:414-419. http: //dx.doi.org/10.1016/j.ijantimicag.2012.01.005.
8. Spigaglia P, Barbanti F, Mastrantonio P. 2011. Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother 66:2227-2234. http://dx.doi.org/10.1093/jac/dkr292.
9. Alcala L, Martin A, Marin M, Sanchez-Somolinos M, Catalan P, Pelaez T, Bouza E. 2012. The undiagnosed cases of Clostridium difficile infection in a whole nation: where is the problem? Clin Microbiol Infect 18:E204-E213. http://dx.doi.org/10.1111/j.1469-0691.2012.03883.x.
10. Ackermann G, Adler D, Rodloff AC. 2003. In vitro activity of linezolid against Clostridium difficile. J Antimicrob Chemother 51:743-745. http: //dx.doi.org/10.1093/jac/dkg113.
11. Persson S, Torpdahl M, Olsen KE. 2008. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect 14:1057-1064. http://dx.doi.org/10.1111/j.1469 -0691.2008.02092.x.
12. Lemee L, Dhalluin A, Testelin S, Mattrat MA, Maillard K, Lemeland JF, Pons JL. 2004. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (toxin A), and tcdB (toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 42:5710-5714. http://dx.doi.org/10.1128 /JCM.42.12.5710-5714.2004.
13. th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Hong T, Li X, Wang J, Sloan C, Cicogna C. 2007. Sequential linezolidresistant Staphylococcus epidermidis isolates with G2576T mutation. J Clin Microbiol 45:3277-3280. http://dx.doi.org/10.1128/JCM.02048-06.
15. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeno-Tarraga AM, Wang H, Holden MT, Wright A, Churcher C, Quail MA, Baker S, Bason N, Brooks K, Chillingworth T, Cronin A, Davis P, Dowd L, Fraser A, Feltwell T, Hance Z, Holroyd S, Jagels K, Moule S, Mungall K, Price C, Rabbinowitsch E, Sharp S, Simmonds M, Stevens K, Unwin L, Whithead S, Dupuy B, Dougan G, Barrell B, Parkhill J. 2006. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 38:779-786. http://dx.doi.org/10.1038/ng1830.
16. Stubbs SL, Brazier JS, O'Neill GL, Duerden BI. 1999. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37:461-463.
17. van den Berg RJ, Schaap I, Templeton KE, Klaassen CH, Kuijper EJ. 2007. Typing and subtyping of Clostridium difficile isolates by using mul-tiple-locus variable-number tandem-repeat analysis. J Clin Microbiol 45: 1024-1028. http://dx.doi.org/10.1128/JCM.02023-06.
18. Mendes RE, Hogan PA, Streit JM, Jones RN, Flamm RK. 2014. Zyvox annual appraisal of potency and spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12). J Antimicrob Chemother 69: 1582-1588. http://dx.doi.org/10.1093/jac/dkt541.
19. Mendes RE, Flamm RK, Hogan PA, Ross JE, Jones RN. 2014. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States. Antimicrob Agents Chemother 58:1243-1247. http://dx.doi.org/10.1128/AAC.02112-13.
20. Dingle KE, Elliott B, Robinson E, Griffiths D, Eyre DW, Stoesser N, Vaughan A, Golubchik T, Fawley WN, Wilcox MH, Peto TE, Walker AS, Riley TV, Crook DW, Didelot X. 2014. Evolutionary history of the Clostridium difficile pathogenicity locus. Genome Biol Evol 6:36-52. http: //dx.doi.org/10.1093/gbe/evt204.
21. Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Pelaez B, Andrade R, de la Torre MA, Fereres J, Sanchez-Garcia M. 2010. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 50:821-825. http://dx.doi.org/10.1086/650574.
22. rd Intersci Conf Antimicrob Agents Chemother. http://www .icaac.org/.
23. Chilton CH, Crowther GS, Baines SD, Todhunter SL, Freeman J, Locher HH, Athanasiou A, Wilcox MH. 2014. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother 69:697-705. http://dx.doi.org/10.1093/jac/dkt411.
24. Locher HH, Seiler P, Chen X, Schroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, Ritz D. 2014. Cadazolid, a new antibiotic for the treatment of Clostridium difficile infections: in vitro and in vivo antibacterial evaluation. Antimicrob Agents Chemother 58:892-900. http: //dx.doi.org/10.1128/AAC.01830-13.